The global ulcerative colitis market size was valued at USD 636.98 million in 2023 and is expected to grow at a CAGR of 6.43% during the forecast period 2024-2030. One of the key driving factors attributed to the growth of the ulcerative colitis market is the increasing prevalence of the disease. Additionally, heightened awareness of ulcerative colitis among healthcare professionals and patients, along with advances in diagnostic techniques, has led to earlier and more accurate diagnoses.
The ulcerative colitis market faced significant disruptions due to the COVID-19 pandemic. This was primarily driven by a shift in healthcare priorities towards COVID-19 treatment, alterations in supply chains, and a surge in research efforts related to COVID-19 products, taking precedence over other treatment areas. However, as the impact of COVID-19 on the general population diminished over time, market players redirected their attention towards addressing various diseases, including developing and promoting ulcerative colitis treatment products, thereby boosting overall market growth.
Furthermore, the development of more effective and targeted therapies as well as the approval of the drugs has significantly contributed to market growth. Biologic drugs, such as anti-TNF agents and integrin inhibitors, have improved patient outcomes and provided alternatives for those who do not respond to conventional treatments. For instance, in 2021, the European Commission has granted marketing authorization to Bristol Myers Squibb for Zeposia (ozanimod), allowing its use in treating adults dealing with moderate to severely active ulcerative colitis (UC). This approval applies to individuals who have not responded adequately, lost their response, or cannot tolerate either traditional therapy or a biologic agent.
Based on the drug type, the ulcerative colitis market is segmented into calcineurin inhibitors, anti-inflammatory drugs, anti-TNF biologics, immunosuppressants, and others. The calcineurin inhibitors segment held the largest market share in 2023 as they offer a unique mechanism of action that effectively suppresses the immune response underlying the inflammation in ulcerative colitis. Medications like tacrolimus and cyclosporine, both calcineurin inhibitors, have shown efficacy in managing moderate to severe cases of ulcerative colitis. On the other hand, anti-inflammatory drugs is anticipated to witness a lucrative growth over the forecast period.
Based on disease type, the market is segmented into proctosigmoiditis, ulcerative proctitis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis. The proctosigmoiditis segment dominated the market in 2023 as it represents a common and frequently diagnosed disease subtype. This form of ulcerative colitis is characterized by inflammation limited to the rectum and sigmoid colon, making it less extensive than other disease types. On the other hand, the fulminant colitis segment is expected to witness significant growth over the forecast period.
Europe dominated the market in 2023. This large share is due to the presence of major industry players and a growing incidence of ulcerative colitis in the region, coupled with sustained funding for developing innovative ulcerative colitis treatment solutions. On the other hand, Latin America is expected to witness lucrative growth over the forecast period.
The following are the leading companies in the ulcerative colitis market. These companies collectively hold the largest market share and dictate industry trends. Financials, strategy maps & products of these ulcerative colitis companies are analyzed to map the supply network.
Key players operating in the market are AbbVie Inc. (Allergan, Inc.), Bausch Health Companies Inc., Johnson & Johnson, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Eli Lilly and Company, Novartis AG, Bristol Myers Squibb, Mitsubishi Tanabe Pharma Corporation, and Sun Pharmaceutical Industries Ltd. The market participants are working towards new product development, M&A activities, and other strategic alliances to gain new market avenues. In April 2023, Merck & Co., Inc. completed an agreement to purchase Prometheus Biosciences for USD 200.00 per share, resulting in a total equity valuation of approximately USD 10.8 billion. This acquisition allows Prometheus Biosciences to fully harness the potential of PRA023, an advanced candidate in late-stage development designed to address conditions such as ulcerative colitis, Crohn's disease, and various autoimmune disorders.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."